Post marketing surveillance on safety and efficacy of IMOD in iranian patients with HIV/AIDS

Infectious Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 71-74

  Mohraz, Minoo ^a   Sedaghat, Abbas ^b   SeyedAlinaghi, SeyedAhmad ^a   Asheri, Hossein ^a   Mohammaddoust, Saeid ^a   Gharibdoost, Farhad ^c   Khorshid, Hamid Reza Khorram ^d   Farhadi, Mohammad ^c   Madani, Seyed Hesamedin ^e   Kamali, Koorosh ^f  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^e Rabe Rashidi Institute Iran   (Iran)

^f AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

Efficacy; IMOD ; Post marketing surveillance; Safety; Satisfaction; Side effect

Indexed keywords

ANTIINFECTIVE AGENT; IMOD; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GASTRITIS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRAN; MALE; NAUSEA; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PHLEBITIS; PHYSICIAN; RASH; VERTIGO;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ATTITUDE OF HEALTH PERSONNEL; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOMODULATION; INFUSIONS, INTRAVENOUS; IRAN; LYMPHOCYTE COUNT; MALE; PATIENT SATISFACTION; PHYSICIANS; PLANT EXTRACTS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84878759257     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/18715265112129990031     Document Type: Article

References (22)

1. Barre-Sinoussi, F.; Chermann, J.C.; Rey, F.; Nugeyre, M.T.; Chamaret, S.; Gruest, J. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983, 220, 868-871.
2. Singh, A.; Bairy, I.; Shivananda, P.G. Spectrum of opportunistic infections in AIDS cases. Indian J. med. Sci., 2003, 57(1), 16-21.
3. Fellay, J.; Boubaker, K.; Ledergerber, B.; Bernasconi, E.; Furrer, H.; Battegay, M.; Hirschel, B.; Vernazza, P.; Francioli, P.; Greub, G.; Flepp, M.; Telenti, A. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, 2001, 358(9290), 1322-1327.
4. Murphy, R.A.; Sunpath, H.; Kuritzkes, D.R.; Venter, F.; Gandhi, R.T. Antiretroviral Therapy-Associated Toxicities in the Resource-Poor World: the Challenge of a Limited Formulary. J. Infect. Dis., 2007, 196 Suppl 3, S449-456.
5. Cerqueira, D.M.; Amorim, R.M.; Silva, R.R.; Camara, G.N.; Brigido, M.M.; Martins, C.R. Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem. Inst. Oswaldo Cruz, 2004, 99(8), 877-882.
6. Hunt, P.W.; Deeks, G.G. Immune-based therapy for HIV infection: are acute and chronic HIV infection different diseases? J. infect. Dis., 2006, 194, 1632-1634.
7. Novitsky, Y.A.; Madani, H.; Gharibdoust, F.; Farhadi, M.; Farzamfar, B.; Mohraz, M. EU Patent Application 087825, 2007.
8. Khorram Khorshid, H.R.; Abdollahi, M.; Novitsky, Y.A.; Shahhosseiny, M.H.; Sadeghi, B.; Madani, H.; Rahimi, R.; Farzamfar, B. Studies on potential Mutagenic and Genotoxic activity of Setarud. Daru, 2008, 16(4), 223-228.
9. Khorram Khorshid, H.R.; Azonov, J.A.; Novitsky, Y.; Shahhosseiny, M.H. Hepatoprotective effects of setarud against carbon tetrachloride-induced liver injury in rats. Ind. J. Gastro., 2008, 27, 110-112.
10. Azonov, J.A.; Khorram Khorshid, H.R.; Novitsky, Y.A.; Farhadi, M.; Ghorbanoghli, Z.; Shahhosseiny, M.H. Protective effects of setarud (IMODTM) on development of diet-induced hypercholesterolemia in rabbits. Daru, 2008, 16(4), 218-222.
11. Khairandish, P.; Mohraz, M.; Farzamfar, B.; Abdollahi, M.; Shahhosseiny, M.H.; Madani, H.; Sadeghi, B.; Heshmat, R.; Gharibdoust, F.; Khorram Khorshid, H.R. Preclinical and phase 1 clinical safety of Setarud (IMOD™), a novel candidate immune modulator drug. Daru, 2009, 17(3), 148-156.
12. Yalda, A.; Seyyed Alinaghi, S.A.; Hajiabdolbaghi, M. Adherence to antiretroviral therapy and its determinants in AIDS patients: review article. Tehran University Medical Journal, 2008, 66 (7), 447-455.
13. Keiser, O.; Fellay, J.; Opravil, M.; Hirsch, H.H.; Hirschel, B.; Bernasconi, E.; Vernazza, P.L.; Rickenbach, M.; Telenti, A. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antivir. Ther., 2007, 12, 1157-1164.
14. Nunez, M.J.; Martin-Carbonero, L.; Moreno, V.; Valencia, E.; Garcia-Samaniego, J.; Castillo, J.G.; Barreiro, P. Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res. Hum. Retroviruses, 2006, 22(9), 825-829.
15. Simon, V.; Vanderhoeven, J.; Hurley, A.; Ramratnam, B.; Louie, M.; Dawson, K.; Parkin, N.; Markowitz, M. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS., 2002, 16(11), 1511-1519.
16. Gallego, O.; Ruiz, L.; Vallejo, A.; Clotet, B.; Leal, M.; Soriano, V. Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J. Clin. Microbiol., 2002, 40(10), 3865-3866.
17. Yerly, S.; Von Wyl, V.; Boni, J.; Schupbach, J.; Burgisser, P.; Klimkait, T.; Rickenbach, M.; Ledergerber, B.; Kaiser, L.; Günthard, HF.; Perrin, L. Swiss HIV Cohort Study: Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS, 2007, 21, 2223-2229.
18. Schwartlander, B.; Stover, J.; Walker, N.; Bollinger, L.; Gutierrez, J.P.; McGreevey, W.; Opuni, M.; Forsythe, S.; Kumaranayake, L.; Watts, C.; Bertozzi, S. Resource Needs for HIV/AIDS. Science, 2001, 292, 2434-2436.
19. Halkitis, P.N.; Wilton, L. Beyond complacency: the effects of treatment on HIV transmission. Focus, 1999, 14(5), 1-4.
20. Roca, B.; Gómez, C.J.; Arnedo, A. Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy. J. Infect., 1999, 39 (2), 141-5.
21. Gifford, A.L.; Collins, R.; Timberlake, D.; Schuster, M.A.; Shapiro, M.F.; Bozzette, S.A.; Kanouse, D.E. Propensity of HIV patients to seek urgent and emergent care. HIV Cost and Services Utilization Study Consortium. J. Gen. Intern. Med., 2000, 15(12), 833-840.
22. Mohraz, M.; Kheirandish, P.; Kazerooni, P.A.; Davarpanah, M.A.; Shahhosseini, M.H. A clinical trial on the efficacy of IMOD in AIDS patients. Daru, 2009, 17(4), 277-284.